SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at two investor conferences in September:
-- Merriman Curhan Ford's 5th Annual Investor Summit to be held at the Mark Hopkins InterContinental Hotel in San Francisco on Monday, September 15, 2008 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time); and
-- UBS's 2008 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on Tuesday, September 23, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time).
Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation date.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix for the drug delivery,
metabolism, oncology, and dermatology markets. The company's portfolio of
products and product candidates is based on intellectual property covering
the family of human enzymes known as hyaluronidases. The company's
Enhanze(TM) Technology is a novel drug delivery platform designed to
increase the absorption and dispersion of biologics. Its key partnerships
are with Roche to apply Enhanze Technology to Roche's biological
therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze
Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID
10%. In addition, the company has received FDA approval for two products:
Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an
adjuvant to increase the absorption and dispersion of other injected drugs
and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme
also has a number of different enzymes in its portfolio that target
significant areas of unmet medical need. For more information visit
Robert H. Uhl Senior Director, Investor Relations
Karen Sparks / Joleen Schultz
(858) 455-5500, x275/x215
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved